⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 15, 2025Expert Review of Gastroenterology & Hepatology

Treatment optimization of subcutaneous infliximab in patients with inflammatory bowel disease

Ajay Gade Alessandra Saraga Tina Deyhim Grace GEEGANAGE Adam S Cheifetz Konstantinos Papamichael Alessandra Saraga

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to optimize the treatment of subcutaneous infliximab in inflammatory bowel disease (IBD) patients.
Analyzed the effectiveness of dose escalation of subcutaneous infliximab (SC-IFX)
Evaluated the roles of drug clearance, immunogenicity, and therapeutic drug monitoring (TDM)
Assessed the impact of body mass index and concomitant IMM therapy
Found that higher drug concentrations correlate with better outcomes
Identified gaps in understanding the role of drug clearance and immunogenicity in treatment
Noted the need for further studies on SC-IFX efficacy in complicated IBD phenotypes

Implication

Research demonstrates the impact of therapeutic drug monitoring and body mass index on clinical outcomes in IBD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gade et al. (2025) studied this question.

synapsesocial.com/papers/6925198ec0ce034ddc3534dd https://doi.org/10.1080/17474124.2025.2591151

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease2025 · 4 citations
2Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry2024 · 20 citations
3Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations2024 · 4 citations
4Treatment persistence and efficacy of subcutaneous infliximab monotherapy in patients with inflammatory bowel disease: a real-world settingCohort Study · 2026
5P0977Treatment persistence and efficacy of subcutaneous infliximab monotherapy in patients with Inflammatory Bowel Disease: a real-world settingCohort Study · 2026